Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555486 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
A Phase 1 study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04555486: Completed Phase 1 study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
NCT04555486 is a Phase 1 study that has completed, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04555486, a Phase 1 study, has completed, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
Primary Outcome
Number of patients with abnormalities in clinically significant laboratory results, vital signs, and 12-lead ECG findings
Interventions
- DRUG Sterile Normal Saline (0.9% NaCl)
- DRUG DCR-PHXC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 1 |
What the finished NCT04555486 record still lists
NCT04555486 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Sterile Normal Saline (0.9% NaCl) is the first listed.
NCT04555486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04555486 about?
NCT04555486 is a clinical study titled "Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients". The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
What is the current status of trial NCT04555486?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-09-14. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT04555486?
The interventions under investigation include: Sterile Normal Saline (0.9% NaCl) (DRUG), DCR-PHXC (DRUG).
Who is sponsoring clinical trial NCT04555486?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04555486's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI